Evidence map›Paper›PMID 40926274›Full record

ArticleBMC global and public health2025

Genomic and clinical epidemiology of SARS-CoV-2 in coastal Kenya: insights into variant circulation, reinfection, and multiple lineage importations during a post-pandemic wave.

Arnold W Lambisia, Esther N Katama, Edidah Moraa, John M Mwita, Katherine Gallagher, Martin Mutunga, Emily Nyale, Joan Omungala, Mike Mwanga, Nickson Murunga and 11 more

Abstract read
In one paragraph

Article in BMC global and public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Arnold W LambisiaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya. alambisia@kemri-wellcome.org.
Esther N KatamaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Edidah MoraaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
John M MwitaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Katherine GallagherKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Martin MutungaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Emily NyaleKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Joan OmungalaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Mike MwangaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Nickson MurungaKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Joyce NyiroKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
James NyagwangeKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Charles SandeKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Philip BejonKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
George GithinjiKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Simon DellicourSpatial Epidemiology Lab (SpELL), Université Libre de Bruxelles, Brussels, Belgium.
My V T PhanCollege of Health Solutions, Arizona State University, Phoenix, AZ, USA.
Matthew CottenCollege of Health Solutions, Arizona State University, Phoenix, AZ, USA.
L Isabella Ochola-OyierKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.
Edward C HolmesSchool of Medical Sciences, University of Sydney, Sydney, Australia.
Charles N AgotiKenya Medical Research Institute (KEMRI) - Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya.

Funding

a National Health and Medical Research Council (Australia) GNT2017197European Union Horizon 2020 projects MOOD n°874850Fonds National de la Recherche Scientifique n°F.4515.22Research Foundation - Flanders n°G098321NWellcome 226002/A/22/ZWellcome 226130/Z/22/ZWellcome Trust
6 · The paper itself

Abstract

backgroundBetween November 2023 and March 2024, coastal Kenya experienced another wave of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections detected through our continued genomic surveillance. Herein, we report the clinical and genomic epidemiology of SARS-CoV-2 infections from 179 individuals (a total of 185 positive samples) residing in the Kilifi Health and Demographic Surveillance System (KHDSS) area (~ 900 km

methodsWe analyzed genetic, clinical, and epidemiological data from SARS-CoV-2 positive cases across pediatric inpatient, health facility outpatient, and homestead community surveillance platforms. Phylogenetic analyses were performed using maximum-likelihood and Bayesian frameworks. Temporal trends were summarized, comparisons conducted using Kruskal-Wallis and Wilcoxon tests, and associations examined using univariate and multivariable logistic regression models.

resultsSixteen SARS-CoV-2 lineages within 3 subvariants [XBB.2.3-like (58.4%), JN.1-like (40.5%), and XBB.1-like (1.1%)] were identified. The symptomatic infection rate was estimated at 16.0% (95% CI, 11.1-23.9%) based on community testing regardless of symptom status and did not differ across the subvariants (p = 0.13). The most common infection symptoms in community cases were cough (49.2%), fever (27.0%), sore throat (7.3%), headache (6.9%), and difficulty in breathing (5.5%). One case succumbed to the infection. Genomic analysis of the virus from serial positive samples confirmed repeat infections among 5 participants under follow-up (median interval 21 days, range 16-95 days); in 4 participants, the same virus lineage was responsible in both episodes, whereas 1 participant had a different lineage in the second compared with the first episode. Phylogenetic analysis including > 18,000 contemporaneous global sequences provided evidence for at least 38 independent virus introduction events into the study area (KHDSS) during the wave, the majority likely originating in North America and Europe.

conclusionsOur study highlights that coastal Kenya, like most other localities, continues to face new SARS-CoV-2 infection waves characterized by circulation of new variants, multiple lineage importations, and reinfections. Locally, the virus may circulate unrecognized, as most infections are asymptomatic in part due to high population immunity after several waves of infection. Our findings highlight the need for sustained SARS-CoV-2 surveillance to inform appropriate public health responses, such as scheduled vaccination for populations at risk of severe infection.

Indexed as

Coastal KenyaCOVID-19JN.1OmicronReinfectionsSARS-CoV-2XBB.2.3

Identifiers

PMID40926274
PMCPMC12421758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.